| Literature DB >> 33723737 |
Margaux Visse1, Véronique Vernet-Garnier2, Odile Bajolet3, Delphine Lebrun4, Morgane Bonnet5, Maxime Hentzien1, Xavier Ohl6, Saidou Diallo6, Firouzé Bani-Sadr7.
Abstract
The objective of this study was to evaluate antimicrobial therapy outcomes of bone and joint infections (BJI) caused by Clostridium perfringens. We investigated remission of symptoms and the absence of relapse or reinfection during follow-up. Among the 8 patients with C. perfringens BJI, the type of infection was early prosthesis infection (n = 2), osteosynthetic device infection (n = 4), and chronic osteomyeletis (n = 2). Clindamycin-rifampicin combination was given in 4 cases and metronidazole in 4 cases. The overall success rate was 87.5%. Among the 7 patients who completed antibiotic treatment, the success rate was 100%. The clindamycin-rifampicin combination appeared to be effective in patients with C. perfringens BJI.Entities:
Keywords: Bone infection; Clindamycin-rifampicin; Clostridium perfringens; Metronidazole
Mesh:
Substances:
Year: 2021 PMID: 33723737 DOI: 10.1007/s10096-021-04225-2
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN: 0934-9723 Impact factor: 3.267